Indian Pharmaceutical Alliance(formerly Indian Pharmaceutical Association)

DeRisk Affordable Medicine Supply Chain; seeking Partnership with US Government & Allies

🤖

AI Overview

With $1.0M in lobbying spend across 13 quarterly filings, Indian Pharmaceutical Alliance(formerly Indian Pharmaceutical Association) is a significant lobbying presence. Their lobbying covers 6 issue areas. Active from 2024 to 2025.

$1.0M
Total Spend
2
Years Active
1
Firms Hired
1
Lobbyists Deployed
6
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2024$75K
2025$945K

Issues Lobbied

Lobbying Firms

Lobbyists

Government Agencies Targeted

These are the government entities that Indian Pharmaceutical Alliance(formerly Indian Pharmaceutical Association) disclosed contacting in their lobbying filings.

Centers For Medicare and Medicaid Services (CMS)Food & Drug Administration (FDA)Health & Human Services, Dept of (HHS)HOUSE OF REPRESENTATIVESNatl Security Council (NSC)SENATEState, Dept of (DOS)U.S. Trade Representative (USTR)White House OfficeFederal Trade Commission (FTC)Commerce, Dept of (DOC)Office of Management & Budget (OMB)Treasury, Dept ofNatl Economic Council (NEC)
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Trade, Homeland Security, Defense, Disaster Planning and 1 more

IPA seeks a sectoral trade agreement with the US to derisk both countries' affordable medicine supply chain. The partnership construct is intended to be expanded to include other trusted allies.

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.